Home Cart Sign in  
Chemical Structure| 25013-16-5 Chemical Structure| 25013-16-5

Structure of Butylhydroxyanisole
CAS No.: 25013-16-5

Chemical Structure| 25013-16-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Butylhydroxyanisole is an antioxidant, consisting of a mixture of two isomeric organic compounds, used as a food additive preservative

Synonyms: Butylated hydroxyanisole; BHA; E320

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Butylhydroxyanisole

CAS No. :25013-16-5
Formula : C11H16O2
M.W : 180.24
SMILES Code : OC1=CC=C(C=C1C(C)(C)C)OC.OC2=CC=C(C(C(C)(C)C)=C2)OC
Synonyms :
Butylated hydroxyanisole; BHA; E320
MDL No. :MFCD01779059
InChI Key :MRBKEAMVRSLQPH-UHFFFAOYSA-N
Pubchem ID :8456

Safety of Butylhydroxyanisole

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H350-H411
Precautionary Statements:P201-P202-P264-P270-P280-P301+P312-P308+P313-P330-P403-P501
Class:9
UN#:3077
Packing Group:

Isoform Comparison

Biological Activity

Description
Butylhydroxyanisole (Butylated hydroxyanisole) serves as an antioxidant and food additive preservative, known to cause liver toxicity, impair the development of reproductive organs, and contribute to learning and sleep deficits. Additionally, it has been found to disrupt brain and nerve development through its neurotoxic effects[1].[2].[3].

In Vitro:

Cell Line
Concentration Treated Time Description References
Rat aortic smooth muscle cells 300 μM 24 h To investigate the effect of BHA on HO-1 gene expression, results showed that BHA stimulated HO-1 protein, mRNA, and promoter activity in a time- and concentration-dependent manner. Cardiovasc Res. 2007 Apr 1;74(1):169-79
U118MG human glioblastoma cell lines 200 μM 8 h To study the effect of BHA on ErPC3-induced collapse of the mitochondrial membrane potential. BHA significantly reduced the number of cells undergoing Δψm collapse otherwise induced by ErPC3. Apoptosis. 2010 Jul;15(7):753-68
U87MG human glioblastoma cell lines 200 μM 6 h To study the effect of BHA on ErPC3-induced collapse of the mitochondrial membrane potential. BHA significantly reduced the number of cells undergoing Δψm collapse otherwise induced by ErPC3. Apoptosis. 2010 Jul;15(7):753-68
mouse bone marrow-derived cells 100 μM 6 days BHA blocked the differentiation of M2 macrophages but had no significant effect on M1 macrophage differentiation Cell Res. 2013 Jul;23(7):898-914
human primary monocytes 100 μM 1 h BHA inhibited GM-CSF- or M-CSF-induced monocyte-macrophage differentiation but had no effect on M1 macrophage differentiation Cell Res. 2013 Jul;23(7):898-914

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Male Sprague Dawley rats Rat carotid artery balloon injury model Local perivascular delivery 1 mg Single administration, lasted for 2 weeks To investigate the effect of BHA on neointima formation, results showed that BHA markedly attenuated neointima formation following balloon injury. Cardiovasc Res. 2007 Apr 1;74(1):169-79
C57BL/6J mice Wild-type C57BL/6J mice Oral gavage 200 mg/kg Once a day for 3 days To investigate the effect of BHA-mediated NRF2 activation on pharmacological activation of FXR. Results showed that BHA treatment significantly suppressed GW4064-induced expression of FXR target genes Shp, Slc17a4, SR-B1, and Saa1. Antioxidants (Basel). 2022 Feb 12;11(2):370
BALB/c mice RSV infection model Oral 50-250 mg/kg Once daily for 7 days BHA treatment significantly attenuated RSV-induced lung oxidative stress, reduced clinical illness and body weight loss, inhibited neutrophil recruitment to the lung, and significantly reduced pulmonary cytokine and chemokine production after RSV infection. Am J Respir Crit Care Med. 2006 Dec 15;174(12):1361-9

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00752102 Chronic Kidney Disease ... More >> Vitamin D Deficiency Coronary Calcification Disorders of Calcium and Bone Metabolism Less << Phase 4 Completed - United States, Pennsylvania ... More >> Hospital of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19107 Less <<
NCT00302952 - Completed - -
NCT02286921 Castration Resistant Metastati... More >>c Prostate Cancer Less << Phase 2 Active, not recruiting December 2019 United States, District of Col... More >>umbia Sibley Memorial Hospital Washington, District of Columbia, United States, 20016 United States, Maryland SKCCC at Johns Hopkins Baltimore, Maryland, United States, 21205 Less <<
NCT00752102 - Completed - -
NCT00302952 Rheumatoid Arthritis Phase 2 Completed - United States, Alabama ... More >> University of Alabama Birmingham, Alabama, United States, 35294 United States, California University of California, San Francisco San Francisco, California, United States, 94143 United States, Colorado University of Colorado Aurora, Colorado, United States, 80095 United States, Illinois University of Chicago Medical Center Chicago, Illinois, United States, 60637 United States, Michigan Justus J. Fiechtner, MD, PLLC Lansing, Michigan, United States, 48910 United States, New York Feinstein Institute for Medical Research NS-LIJ Health System Manhasset, New York, United States, 11030 University of Rochester Rochester, New York, United States, 14642 United States, North Carolina Carolina Bone and Joint Charlotte, North Carolina, United States, 29425 Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Oklahoma Oklahoma Medical Research Foundation Oklahoma City, Oklahoma, United States, 73104 United States, Pennsylvania Altoona Center for Clinical Research Duncansville, Pennsylvania, United States, 16635 University of Pittsburgh Medical Center Pittsburgh, Pennsylvania, United States, 15261 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 United States, Texas Baylor Research Institute Dallas, Texas, United States, 75231 United States, Utah University of Utah Salt Lake City, Utah, United States, 84132 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.55mL

1.11mL

0.55mL

27.74mL

5.55mL

2.77mL

55.48mL

11.10mL

5.55mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories